Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacokinetic and pharmacodynamic properties of plasma-derived vs. recombinant factor IX in patients with hemophilia B: a prospective crossover study.

Journal of thrombosis and haemostasis : JTH - 1 Dec 2014

Alamelu J, Bevan D, Sorensen B, Rangarajan S

Abstract excerpt

BACKGROUND: Effective treatment of acute bleeding episodes in patients with hemophilia B relies on factor IX recovery, with higher levels being more desirable, whereas prevention of bleeds with a prophylactic regimen depends on the half-life of the product. Lower recovery values have been reported following administration of recombinant FIX (rFIX) than following administration of plasma-derived FIX (pdFIX)....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cross-Over Studies
Share to Factor IX

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Hemophilia B

Share to Recombinant Proteins

Share to Reproducibility of Results

Share to Thrombin

Share to Time Factors

Share to Young Adult

Source

Identifiers

PMID: 25315324
DOI: 10.1111/jth.12756

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacokinetic and pharmacodynamic properties of plasma-derived vs. recombinant factor IX in patients with hemophilia B: a prospective crossover study.PMID 25315324Read ↗

Characterization of recombinant factor IX fusion proteins enabling subcutaneous administration.Semantic proximity Read ↗

Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX.Semantic proximity Read ↗

Monitoring once-weekly recombinant factor IX prophylaxis in hemophilia B with thrombin generation assay and factor IX activity.Semantic proximity Read ↗

In vitro comparison of the effect of two factor XI (FXI) concentrates on thrombin generation in major FXI deficiency.Semantic proximity Read ↗

Genetic fusion to albumin improves the pharmacokinetic properties of factor IXSemantic proximity Read ↗

In vitro evaluation of factor IX as novel treatment for factor XI deficiencySemantic proximity Read ↗

Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. The Mononine Study Group.Semantic proximity Read ↗

Transition considerations for extended half‐life factor productsSemantic proximity Read ↗

Efficacy, safety and pharmacokinetics of a new high-purity factor X concentrate in women and girls with hereditary factor X deficiency.Semantic proximity Read ↗

Variable pharmacokinetics of coagulation factor VIII in the perioperative setting complicates personalisation of treatment in patients with haemophilia ASemantic proximity Read ↗

Variants of recombinant factor VIIa with increased intrinsic activity.Semantic proximity Read ↗

Correlation between FIX genotype and pharmacokinetics of Nonacog alpha according to a multicentre Italian study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.